ArticleOncology letters2025
Association of recurrence with patient and tumor factors in gastrointestinal stromal tumors of small intestine: A single-institutional retrospective study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predicting the prognosis of small intestinal stromal tumors in the post-imatinib era: a study based on the SEER database.Translational cancer research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are relatively rare, with 35% of GISTs occurring in the small intestine. The recurrence rate of small intestinal GISTs is higher than that of gastric GISTs. The present study aimed to identify the factors involved in the recurrence of small intestinal GISTs using data obtained from patients treated at Chiba University Graduate School of Medicine (Chuo, Japan). Overall, 27 lesions in 26 patients who underwent radical resection for small intestinal GISTs at Chiba University Hospital between January 2002 and December 2021 were retrospectively analyzed to determine the association between clinicopathological factors and recurrence. Recurrence occurred in 9 out of the 26 patients. A univariate nominal logistic analysis revealed that jejunal lesions, tumor size ≥60 mm, maximum standardized uptake value ≥8.4, mitotic count ≥4/50 high power field, Ki-67 index ≥10%, neutrophil-to-lymphocyte ratio (NLR) ≥3.7, platelet-to-lymphocyte ratio ≥227 and Onodera's prognostic nutritional index ≤51 were significantly associated with postoperative recurrence. The NLR was moderately correlated with tumor size and Ki-67 index. This study has revealed that patient and tumor factors are associated with the recurrence of small intestinal GISTs. Elucidating the fundamental mechanisms linking inflammatory and nutritional indicators to tumor recurrence may provide novel insights into the progression and treatment strategies required for small intestinal GISTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.